# Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

> **NCT03421236** · PHASE1 · UNKNOWN · sponsor: **Patrice Jichlinski** · enrollment: 25 (estimated)

## Conditions studied

- Non Muscle Invasive Bladder Cancer

## Interventions

- **BIOLOGICAL:** Ty21a

## Key facts

- **NCT ID:** NCT03421236
- **Lead sponsor:** Patrice Jichlinski
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-18
- **Primary completion:** 2021-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2021-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03421236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03421236, "Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03421236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*